GAMMA Investing LLC Buys 214 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

GAMMA Investing LLC boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 58.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 583 shares of the biotechnology company’s stock after purchasing an additional 214 shares during the quarter. GAMMA Investing LLC’s holdings in Ascendis Pharma A/S were worth $80,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of ASND. Loomis Sayles & Co. L P raised its position in shares of Ascendis Pharma A/S by 35.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock valued at $27,566,000 after buying an additional 48,120 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Ascendis Pharma A/S by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after acquiring an additional 4,338 shares during the last quarter. Evolutionary Tree Capital Management LLC raised its position in Ascendis Pharma A/S by 82.3% during the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock valued at $3,391,000 after purchasing an additional 11,223 shares in the last quarter. Valence8 US LP bought a new stake in Ascendis Pharma A/S during the third quarter worth about $685,000. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in shares of Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after purchasing an additional 5,371 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $129.19 on Friday. The stock’s 50-day moving average is $132.61 and its 200 day moving average is $133.58. The company has a market cap of $7.84 billion, a PE ratio of -15.99 and a beta of 0.65. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Stifel Nicolaus raised their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. decreased their target price on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company upped their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $192.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.